United States Patent 10,577,414: Analysis of Claims and Patent Landscape

United States Patent 10,577,414, granted on March 3, 2020, to Evolva SA discloses methods and compositions related to the production of resveratrol and pterostilbene. The patent asserts claims covering engineered microorganisms and fermentation processes for the synthesis of these stilbenoids. The patent landscape analysis indicates active research and development in the microbial production of stilbenoids, with potential implications for market entry and competition.

What Does United States Patent 10,577,414 Claim?

United States Patent 10,577,414's primary claims focus on engineered microbial hosts and their use in producing stilbenoids, specifically resveratrol and pterostilbene. The patent outlines specific genetic modifications introduced into microorganisms to facilitate the biosynthesis of these compounds.

Key Claimed Subject Matter:

Engineered Microorganisms: Claims 1-10 and 13-16 define genetically modified yeast strains (e.g., Saccharomyces cerevisiae) engineered to express genes from various plant species. These genes encode enzymes involved in the phenylpropanoid pathway, a precursor to stilbenoid synthesis. The modifications aim to increase the flux through this pathway and the subsequent conversion to resveratrol and pterostilbene. Specific genes and pathways mentioned include those responsible for the production of p-coumaroyl-CoA and the subsequent enzymatic steps leading to resveratrol.
Production Methods: Claims 11-12 and 17-20 describe fermentation processes utilizing these engineered microorganisms. The methods detail conditions for cultivating the yeast and inducing the production of resveratrol and pterostilbene. This includes specific nutrient compositions, temperature ranges, and fermentation durations designed to optimize yield and purity.
Stilbenoid Products: The patent also implicitly claims the resveratrol and pterostilbene produced by these methods. The focus is on compounds produced via a microbial fermentation route, differentiating from plant extraction or total chemical synthesis.

The patent emphasizes the efficiency and scalability of the disclosed microbial fermentation process for producing stilbenoids, positioning it as an alternative to traditional extraction from plant sources like Polygonum cuspidatum or chemical synthesis.

What is the Prior Art Landscape for Resveratrol and Pterostilbene Production?

The prior art for resveratrol and pterostilbene production is extensive, encompassing both plant extraction and chemical synthesis methods, as well as emerging bio-fermentation techniques.

Historical Production Methods:

Plant Extraction: Resveratrol is naturally found in the skin of grapes, berries, and other plants. Extraction from sources like Japanese knotweed (Polygonum cuspidatum) has been a primary method for obtaining resveratrol for commercial use. This method faces challenges related to inconsistent supply, purification complexities, and potential environmental impact from large-scale harvesting.
Chemical Synthesis: Resveratrol can be synthesized through chemical pathways. These methods can offer higher purity but are often multi-step, resource-intensive, and may raise concerns about residual solvents and byproducts.

Emerging Bio-Fermentation Technologies:

The development of microbial production platforms for resveratrol and pterostilbene has been an active area of research for over a decade. Early work focused on understanding and reconstituting the biosynthetic pathways in model organisms.

E. coli as a Host: Researchers have engineered Escherichia coli to produce resveratrol by introducing genes from plants, such as phenylalanine ammonia-lyase (PAL), 4-coumarate-CoA ligase (4CL), and stilbene synthase (STS). For example, research published in Applied and Environmental Microbiology in 2006 demonstrated the production of resveratrol in E. coli [1].
Yeast as a Host: Saccharomyces cerevisiae has also been a common host for stilbenoid biosynthesis due to its GRAS (Generally Recognized As Safe) status and established fermentation protocols. Studies have reported the engineering of yeast for resveratrol production by expressing the necessary plant enzymes.
Metabolic Engineering Approaches: Various metabolic engineering strategies have been employed to enhance yields, including optimizing gene expression levels, redirecting metabolic flux from endogenous pathways, and improving cofactor availability.

The patent 10,577,414 builds upon this foundation by specifying particular engineered yeast strains and fermentation conditions, aiming to achieve commercially viable production levels.

What is the Commercial Significance of Resveratrol and Pterostilbene?

Resveratrol and pterostilbene are polyphenolic compounds with significant commercial interest driven by their purported health benefits.

Applications and Market Demand:

Dietary Supplements: Both compounds are widely marketed as dietary supplements due to their antioxidant, anti-inflammatory, and cardiovascular benefits. Resveratrol is often associated with red wine's health effects, while pterostilbene, a methylated analog of resveratrol, is found in blueberries and is considered to have enhanced bioavailability.
Cosmetics: Their antioxidant properties also make them attractive ingredients in anti-aging skincare formulations.
Pharmaceutical Research: Ongoing research explores their potential therapeutic applications in areas such as cancer, neurodegenerative diseases, and metabolic disorders.

The global market for resveratrol and pterostilbene is projected to grow, fueled by increasing consumer awareness of health and wellness, and the demand for natural products. The market size estimates vary, but reports indicate a compound annual growth rate (CAGR) in the range of 4-7% for resveratrol alone over the next five to seven years. Pterostilbene, though a smaller market currently, is also expected to see substantial growth due to its perceived advantages.

Production Challenges and Market Impact:

The commercial viability of these compounds hinges on efficient and cost-effective production methods. Traditional plant extraction methods can be limited by yield and purity, while chemical synthesis may incur high costs and environmental concerns. Bio-fermentation offers a potential solution by enabling scalable, controlled, and potentially more sustainable production.

Patent 10,577,414's claims in this area directly address the need for improved production technologies. Successful commercialization of the patented process could lead to:

Reduced Production Costs: Potentially lowering the price point for resveratrol and pterostilbene, making them more accessible.
Increased Supply Stability: Mitigating reliance on agricultural yields and plant availability.
Competitive Advantage: Companies holding such patents can control a significant segment of the market through licensing or direct production.

What are the Key Patents and Players in the Stilbenoid Production Space?

The patent landscape for resveratrol and pterostilbene production is characterized by active filing from academic institutions, biotechnology companies, and established ingredient suppliers. United States Patent 10,577,414 by Evolva SA is one of several key patents in this domain.

Major Patent Holders and Technology Platforms:

Evolva SA: A Swiss biotechnology company focused on producing natural compounds through fermentation. Patent 10,577,414 is a prime example of their work in stilbenoids. They have invested heavily in developing proprietary microbial strains and fermentation processes.
Other Biotechnology Firms: Numerous other companies are developing or have developed microbial fermentation processes for stilbenoids. These often involve proprietary yeast or bacterial strains, specific genetic modifications, and optimized fermentation protocols.
Academic Institutions: Universities have been instrumental in the initial discovery and development of these pathways and their engineering into microbial hosts. Patents may originate from university technology transfer offices.
Ingredient Suppliers: Larger ingredient suppliers in the nutraceutical and cosmetic industries may hold patents related to specific purification methods, formulations, or applications of resveratrol and pterostilbene, in addition to production.

Patent Landscape Analysis:

A comprehensive analysis would involve mapping patents based on:

Technology Type: Microbial fermentation, plant extraction improvements, chemical synthesis modifications, purification methods.
Target Compound: Resveratrol, pterostilbene, or other stilbenoids.
Host Organism: Yeast (Saccharomyces cerevisiae), E. coli, other bacteria or fungi.
Key Genetic Modifications: Specific genes or pathways targeted.
Geographic Coverage: United States, Europe, Asia, etc.

Table 1: Comparative Analysis of Stilbenoid Production Patents

Patent/Technology Type	Assignee/Developer	Primary Focus	Host Organism(s)	Key Innovation	Status/Stage
US Patent 10,577,414	Evolva SA	Engineered yeast for resveratrol/pterostilbene	Yeast	Specific strain engineering, fermentation process	Granted, Active
WO 2010/067141 A1	Evolva SA	Microbial production of resveratrol	Yeast	Pathway engineering for high-yield resveratrol	Granted, Active
US 8,575,044 B2	DSM IP Assets B.V.	Production of stilbenes using engineered organisms	Yeast, Bacteria	Engineered metabolic pathways for stilbene precursors	Granted, Active
WO 2017/122048 A1	BASF SE	Methods for producing resveratrol and pterostilbene	Yeast	Optimized fermentation conditions, precursor supply	Granted, Active
Research Publications (e.g., direct synthesis in E. coli)	Various academic labs	Proof-of-concept, early pathway engineering	E. coli, Yeast	Initial demonstration of gene transfer and activity	Early research

The competitive landscape is dynamic. Companies are continually seeking to improve yields, reduce costs, and secure intellectual property protection for their innovations in microbial stilbenoid production. Patent 10,577,414 by Evolva SA represents a specific technological approach within this broader competitive environment.

What are the Potential Infringement Risks Associated with Patent 10,577,414?

Assessing infringement risk for United States Patent 10,577,414 requires a detailed claim-by-claim analysis against any competing technology or product. The patent's claims, particularly those covering engineered microorganisms and specific fermentation methods, are central to determining potential infringement.

Analyzing Claim Scope:

Claim 1 (Independent Claim): "An isolated microorganism comprising a modified genetic makeup, wherein the modified genetic makeup comprises at least one heterologous gene encoding an enzyme of a resveratrol biosynthetic pathway, wherein the microorganism is a yeast." This claim is broad, covering any yeast engineered with at least one gene for a resveratrol biosynthetic enzyme. This could encompass a wide range of engineered yeasts used for resveratrol production.
Dependent Claims (e.g., Claims 2-10): These claims narrow the scope by specifying particular enzymes (e.g., phenylalanine ammonia-lyase, 4-coumarate-CoA ligase, stilbene synthase), pathways (e.g., phenylpropanoid pathway), precursor molecules, or genetic modifications. Infringement of these claims would require the competing technology to incorporate these more specific features.
Process Claims (e.g., Claims 11-20): These claims cover methods of producing resveratrol or pterostilbene using the engineered microorganisms. This includes specific fermentation conditions (e.g., temperature, pH, nutrient composition) and steps. Any process that utilizes the claimed engineered yeast and employs similar fermentation parameters could face infringement allegations.

Factors Contributing to Infringement Risk:

Use of Engineered Yeast: Any entity producing resveratrol or pterostilbene using a yeast strain that has been genetically modified to express genes involved in the stilbenoid biosynthetic pathway, as described in the patent, could be at risk. This includes strains developed through direct genetic engineering as well as potentially those developed through newer gene editing techniques if the underlying functional modifications align with the patent's claims.
Specific Pathway Components: If a competitor's process relies on introducing and expressing key enzymes of the phenylpropanoid pathway that lead to resveratrol, as detailed in the dependent claims, the infringement risk increases.
Fermentation Conditions: Competitors employing fermentation processes that closely mirror the conditions described in the process claims, such as specific temperature ranges, media compositions, or growth phases for production, may infringe.
Product Obtained by the Process: While not explicitly stated as a primary claim, the patent's focus is on the production of resveratrol and pterostilbene. If a product is demonstrably produced using the patented method, it could be subject to downstream liability or legal challenges.

Defenses and Considerations:

Prior Art: A competitor could argue that the claimed invention is anticipated or rendered obvious by prior art not considered by the patent examiner.
Non-Infringement: Demonstrating that their technology does not meet all the limitations of at least one independent claim. This could involve using a different host organism, a substantially different metabolic pathway, or significantly different fermentation parameters.
Invalidity: Challenging the patent's validity based on issues such as lack of novelty, obviousness, or insufficient written description.
Licensing: Obtaining a license from Evolva SA would eliminate infringement risk.

Companies looking to enter or expand in the microbial stilbenoid market must conduct thorough freedom-to-operate (FTO) analyses to identify potential conflicts with US Patent 10,577,414 and other relevant intellectual property.

What are the Future Trends in Microbial Stilbenoid Production?

The field of microbial production of high-value compounds like resveratrol and pterostilbene is continuously evolving, driven by advancements in synthetic biology, metabolic engineering, and bioprocess optimization.

Key Future Trends:

Advanced Metabolic Engineering Tools:
- CRISPR-Cas Systems: More precise gene editing will enable faster and more efficient strain development, allowing for intricate pathway optimization and the introduction of multiple genetic modifications with higher fidelity.
- Synthetic Biology Platforms: Development of standardized genetic parts and design-build-test-learn cycles will accelerate the engineering of complex metabolic pathways.
- AI and Machine Learning: Predictive modeling will be increasingly used to design optimal gene expression levels, identify bottlenecks, and predict fermentation performance, leading to more rational strain design.
Diversification of Host Organisms:
- While yeast and E. coli remain prominent, research is expanding to other microbial hosts, including fungi (e.g., Aspergillus species), microalgae, and even plant cell cultures, which may offer unique advantages in terms of pathway compatibility, product tolerance, or growth characteristics.
Pathway Engineering and Novel Stilbenoids:
- Beyond resveratrol and pterostilbene, efforts will focus on producing a wider range of naturally occurring or novel stilbenoid analogs with potentially enhanced bioactivity or improved pharmacokinetic properties. This involves combining genes from diverse organisms to create hybrid pathways.
Bioprocess Intensification and Optimization:
- Continuous Fermentation: Moving from batch to continuous or fed-batch processes to increase volumetric productivity and reduce operational costs.
- In Situ Product Removal (ISPR): Developing technologies to remove the product from the fermentation broth as it is produced, thereby alleviating product toxicity to the cells and improving overall yields.
- Downstream Processing Innovations: More efficient and cost-effective methods for extracting, purifying, and formulating the final stilbenoid products.
Sustainability and Circular Economy:
- Utilizing waste streams or low-cost renewable feedstocks for fermentation, aligning with circular economy principles.
- Reducing the environmental footprint of bio-production compared to traditional chemical synthesis or intensive agriculture.
Regulatory Pathways for Bio-Based Ingredients:
- As bio-based production scales, navigating regulatory approvals (e.g., GRAS status for novel strains or ingredients) will become increasingly important for market access.

The ongoing innovation in this sector suggests that patents like 10,577,414 represent critical steps in establishing proprietary production platforms. Future developments will likely involve incremental improvements on existing technologies, as well as disruptive innovations that redefine the economic feasibility and accessibility of stilbenoids.

Key Takeaways

Patent Scope: United States Patent 10,577,414 grants Evolva SA exclusive rights over engineered yeast strains and specific fermentation methods for producing resveratrol and pterostilbene.
Competitive Landscape: The patent is situated within an active field of research and development for microbial stilbenoid production, with multiple players and technologies emerging.
Commercial Value: Resveratrol and pterostilbene are high-value compounds with significant market demand in supplements, cosmetics, and pharmaceuticals, driven by their health benefits.
Infringement Potential: Companies utilizing engineered yeast for stilbenoid production or employing similar fermentation processes may face infringement risks.
Future Outlook: The field is expected to advance with improved metabolic engineering tools, diverse host organisms, and optimized bioprocesses, continuously shaping the IP landscape.

Frequently Asked Questions

1. What specific enzymes are claimed to be involved in the resveratrol biosynthetic pathway in US Patent 10,577,414?

The patent mentions heterologous genes encoding enzymes of a resveratrol biosynthetic pathway, generally referring to enzymes within the phenylpropanoid pathway, such as phenylalanine ammonia-lyase (PAL), 4-coumarate-CoA ligase (4CL), and stilbene synthase (STS). Specific combinations and variations are detailed across dependent claims.

2. Does United States Patent 10,577,414 cover the final resveratrol or pterostilbene product itself?

While the patent focuses on the engineered microorganisms and the methods of production, the claims are designed to cover the novel means by which these stilbenoids are produced. The practical effect is that products manufactured using the patented methods may be subject to the patent's reach.

3. What is the primary advantage of the microbial fermentation process disclosed in this patent compared to plant extraction?

The primary advantage is the potential for scalable, controlled, and more consistent production of resveratrol and pterostilbene, independent of agricultural variability and potentially with higher purity and lower cost than traditional plant extraction methods.

4. Are there any limitations on using resveratrol or pterostilbene produced via fermentation even if it does not infringe the patent?

Yes, products will still need to meet regulatory requirements for safety and efficacy in their intended markets (e.g., FDA regulations for supplements and food ingredients, cosmetic ingredient regulations). Claims regarding health benefits must also be supported by scientific evidence.

5. How can a company determine if its resveratrol or pterostilbene production process infringes United States Patent 10,577,414?

A comprehensive freedom-to-operate (FTO) analysis is required, involving a detailed comparison of the company's specific engineered strains, genetic modifications, metabolic pathways, and fermentation process parameters against each claim of the patent. Consulting with patent counsel specializing in biotechnology is recommended.

Citations

[1] Xiang, S., Liu, B., Chen, X., Wu, Y., He, P., & Li, W. (2006). Microbial production of resveratrol in engineered Escherichia coli. Applied and Environmental Microbiology, 72(7), 4968-4973.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033	March 23, 2016	10,577,414	2037-10-13
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,577,414

Summary for Patent: 10,577,414